A detailed history of Black Rock Inc. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,139,029 shares of CTMX stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,139,029
Previous 1,131,208 0.69%
Holding current value
$1.14 Million
Previous $2.47 Million 43.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.21 - $5.13 $9,463 - $40,121
7,821 Added 0.69%
1,139,029 $1.39 Million
Q1 2024

May 10, 2024

SELL
$1.41 - $2.74 $6,947 - $13,499
-4,927 Reduced 0.43%
1,131,208 $2.47 Million
Q4 2023

Feb 13, 2024

SELL
$1.07 - $1.55 $3,746 - $5,426
-3,501 Reduced 0.31%
1,136,135 $1.76 Million
Q3 2023

Nov 13, 2023

SELL
$1.26 - $1.87 $10,306 - $15,296
-8,180 Reduced 0.71%
1,139,636 $1.47 Million
Q2 2023

Aug 11, 2023

BUY
$1.41 - $1.92 $33,902 - $46,164
24,044 Added 2.14%
1,147,816 $1.97 Million
Q1 2023

May 12, 2023

SELL
$1.48 - $2.88 $260,818 - $507,539
-176,229 Reduced 13.56%
1,123,772 $1.7 Million
Q4 2022

Feb 13, 2023

SELL
$1.19 - $1.91 $594,240 - $953,781
-499,362 Reduced 27.75%
1,300,001 $2.08 Million
Q3 2022

Nov 14, 2022

SELL
$1.23 - $1.97 $33,490 - $53,639
-27,228 Reduced 1.49%
1,799,363 $2.61 Million
Q2 2022

Aug 12, 2022

SELL
$1.53 - $2.89 $4.84 Million - $9.15 Million
-3,165,503 Reduced 63.41%
1,826,591 $3.34 Million
Q1 2022

May 12, 2022

BUY
$2.67 - $4.68 $79,384 - $139,145
29,732 Added 0.6%
4,992,094 $13.3 Million
Q4 2021

Feb 10, 2022

SELL
$3.87 - $7.39 $349,224 - $666,866
-90,239 Reduced 1.79%
4,962,362 $21.5 Million
Q3 2021

Nov 09, 2021

SELL
$4.32 - $6.43 $121,055 - $180,181
-28,022 Reduced 0.55%
5,052,601 $25.7 Million
Q2 2021

Aug 11, 2021

BUY
$6.33 - $9.91 $32.2 Million - $50.3 Million
5,080,623 New
5,080,623 $32.2 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $66M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.